Enliven Therapeutics, Inc.
ELVN
$27.25
-$0.54-1.94%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 462.62M | 477.57M | 490.50M | 289.56M | 313.44M |
| Total Receivables | -- | -- | -- | -- | -- |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | 12.26M | 5.12M | 5.12M | 4.76M | 4.63M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | -- | -- | -- | -- | 54.00K |
| Total Current Assets | 474.88M | 482.68M | 495.62M | 294.32M | 318.13M |
|
|
|||||
| Total Current Assets | 474.88M | 482.68M | 495.62M | 294.32M | 318.13M |
| Net Property, Plant & Equipment | 417.00K | 874.00K | 1.03M | 1.06M | 458.00K |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 873.00K | 7.32M | 7.24M | 7.20M | 7.18M |
| Total Assets | 476.17M | 490.88M | 503.89M | 302.57M | 325.76M |
|
|
|||||
| Total Accounts Payable | 2.16M | 1.43M | 2.35M | 1.56M | 1.34M |
| Total Accrued Expenses | 13.66M | 12.75M | 12.42M | 11.90M | 14.37M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 399.00K | 387.00K | 376.00K | 365.00K | -- |
| Total Finance Division Other Current Liabilities | 351.00K | 86.00K | 63.00K | 146.00K | 204.00K |
| Total Other Current Liabilities | 351.00K | 86.00K | 63.00K | 146.00K | 204.00K |
| Total Current Liabilities | 16.57M | 14.65M | 15.21M | 13.97M | 15.92M |
|
|
|||||
| Total Current Liabilities | 16.57M | 14.65M | 15.21M | 13.97M | 15.92M |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | -- | 103.00K | 204.00K | 302.00K | -- |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | -- | -- | -- | -- | -- |
| Total Liabilities | 16.57M | 14.75M | 15.42M | 14.27M | 15.92M |
|
|
|||||
| Common Stock & APIC | 806.43M | 793.40M | 786.00M | 560.33M | 553.26M |
| Retained Earnings | -347.17M | -317.50M | -297.35M | -272.02M | -243.47M |
| Treasury Stock & Other | 334.00K | 221.00K | -177.00K | -16.00K | 55.00K |
| Total Common Equity | 459.60M | 476.12M | 488.47M | 288.30M | 309.85M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 459.60M | 476.12M | 488.47M | 288.30M | 309.85M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 459.60M | 476.12M | 488.47M | 288.30M | 309.85M |
|
|
|||||